The structure of human SULT1A1 crystallized with estradiol - An insight into active site plasticity and substrate inhibition with multi-ring substrates

被引:91
作者
Gamage, NU
Tsvetanov, S
Duggleby, RG
McManus, ME
Martin, JL [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
[3] Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia
关键词
D O I
10.1074/jbc.M508289200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human SULT1A1 belongs to the supergene family of sulfotransferases (SULTs) involved in the sulfonation of xeno- and endobiotics. The enzyme is also one of the SULTs responsible for metabolic activation of mutagenic and carcinogenic compounds and therefore is implicated in various cancer forms. Further, it is not well understood how substrate inhibition takes place with rigid fused multiring substrates such as 17 beta-estradiol (E2) at high substrate concentrations when subcellular fractions or recombinant enzymes are used. To investigate how estradiol binds to SULT1A1, we co-crystallized SULT1A1 with sulfated estradiol and the cofactor product, PAP (3'-phosphoadenosine 5'-phosphate). The crystal structure of SULT1A1 that we present here has PAP and one molecule of E2 bound in a nonproductive mode in the active site. The structure reveals how the SULT1A1 binding site undergoes conformational changes to accept fused ring substrates such as steroids. In agreement with previous reports, the enzyme shows partial substrate inhibition at high concentrations of E2. A model to explain these kinetics is developed based on the formation of an enzyme(.)PAP(.)E2 dead-end complex during catalysis. This model provides a very good quantitative description of the rate versus the [ E2] curve. This dead-end complex is proposed to be that described by the observed structure, where E2 is bound in a nonproductive mode.
引用
收藏
页码:41482 / 41486
页数:5
相关论文
共 33 条
[1]   Current status of the cytosolic sulfotransferases in the activation of promutagens and procarcinogens metabolic [J].
Banoglu, E .
CURRENT DRUG METABOLISM, 2000, 1 (01) :1-30
[2]   Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3 [J].
Barnett, AC ;
Tsvetanov, S ;
Gamage, N ;
Martin, JL ;
Duggleby, RG ;
McManus, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :18799-18805
[3]   STRUCTURE-ACTIVITY STUDIES OF SULFATE TRANSFER - THE HYDROLYSIS AND AMINOLYSIS OF 3'-PHOSPHOADENOSINE 5'-PHOSPHOSULFATE (PAPS) [J].
BEDFORD, CT ;
KIRBY, AJ ;
LOGAN, CJ ;
DRUMMOND, JN .
BIOORGANIC & MEDICINAL CHEMISTRY, 1995, 3 (02) :167-172
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Crystal structure of human catecholamine sulfotransferase [J].
Bidwell, LM ;
McManus, ME ;
Gaedigk, A ;
Kakuta, Y ;
Negishi, M ;
Pedersen, L ;
Martin, JL .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (03) :521-530
[6]   A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily [J].
Blanchard, RL ;
Freimuth, RR ;
Buck, J ;
Weinshilboum, RM ;
Coughtrie, MWH .
PHARMACOGENETICS, 2004, 14 (03) :199-211
[7]   Structural characterization of human aryl sulphotransferases [J].
Brix, LA ;
Duggleby, RG ;
Gaedigk, A ;
McManus, ME .
BIOCHEMICAL JOURNAL, 1999, 337 :337-343
[8]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[9]  
CHOU HC, 1995, CANCER RES, V55, P525
[10]  
DUFFEL MW, 1981, J BIOL CHEM, V256, P1123